Skip to main content
OpenTrials
Completed

NCT Number: NCT05316259

A Food-Effect Study of BPI-16350 in Healthy Subjects

This study is intended to quantify the effect of food on the pharmacokinetics of BPI-16350.

Subjects will be randomized to a crossover sequence at a 1:1 ratio and administered the dose of BPI-16350 on Day 1 in Period 1 and on Day 15 in Period 2 under fasting conditions(Treatment A) or with a high-fat meal(Treatment B).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Kthics Committee (seal),of Beijing Youan Hospital,Capital Medical University

Beijing, Beijing Municipality, 100069, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects aged 18~45 (including 18 and 45 years old);
  • Male body weight ≥ 50kg, female body weight ≥ 45kg, body mass index (BMI) within the range of 19 ~ 26kg /m2;
  • Clinical laboratory evaluations within the reference range for the test laboratory, unless deemed not clinically significant by the Investigator;
  • The subjects should took effective contraceptive measures voluntarily from informed consent until 3 months after Study Completion;
  • Able to comprehend and willing to sign an informed consent form.

Exclusion criteria

  • History of significant hypersensitivity to any drug compound or food;
  • Significant history or clinical manifestation of any significant cardiovascular, hepatic, renal, pulmonary, gastrointestinal, neurological, metabolic, musculoskeletal,hematological disorder;
  • Hepatitis B virus surface antigen, hepatitis C virus antibody, treponema pallidum antibody or human immunodeficiency virus antibody is positive;
  • Family history of long QTc syndrome; History or presence of an abnormal ECG;
  • Drug abusers, smokers or alcoholics;
  • Use of any medications within 14 days prior to the first administration;
  • Donation of blood ≥ 200 mL or receipt of blood products within 3 months before enrollment, or plan on blood donation during the study period;
  • Participation in any other investigational drug study or receive any vaccine within 3 months before enrollment;
  • Female subjects who are pregnant or lactating;the serum HCG test of women with fertility is postive at Screening.

Treatment and study plan

BPI-16350

Drug

Administered orally

Primary outcomes

  1. Cmax

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Maximum observed concentration

  2. AUC0-t

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Area under the concentration-time curve from time 0 to time t

  3. AUC0-∞

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Area under the concentration-time curve from time 0 to infinity

Secondary outcomes

  1. Tmax

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Time to reach maximum observed plasma concentration

  2. t1/2

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Half-life time

  3. λz

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Elimination rate constant

  4. tlag

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Lag Time

  5. AUC %Extrap

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Percentage of AUCinf due to extrapolation from Tlast to infinity

  6. CL/F

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Apparent Oral Clearance

  7. V/F

    Time frame: from Day 1 to Day 9 after the first dose and from Day 15 to Day 23 after the second dose

    Apparent Volume of Distribution

  8. Characterize the safety of BPI-16350

    Time frame: from Day 1 to Day 23

    Number of subjects with treatment related adverse events

Sponsors and collaborators

Lead sponsor

Betta Pharmaceuticals Co., Ltd.

Industry

Registry information

Official study title

A Phase 1, Single-center, Open-Label, Randomized, 2 Period Crossover Study to Estimate the Effect of Food on the Pharmacokinetics of BPI-16350 in Chinese Healthy Volunteers After a Single Oral Administration

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Apr 7, 2022
Registry last updated
May 9, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.